Comment on CMS-2026-1255-0001

Summary: Castle Biosciences, Inc., a molecular diagnostics company, supports the proposed action to address and reform prior authorization requirements for laboratory tests. They argue that current prior authorization practices—particularly within Medicare Advantage plans—create significant administrative burdens, delay patient care, and lead to improper denials based on procedural technicalities rather than medical necessity.